Huntington Disease - Pipeline Review, H1 2016 illuminated by new report
Huntington Disease - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Huntington Disease pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects.
Complete report available @ Huntington Disease - Pipeline Review, H1 2016
This report is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Huntington Disease
- The report reviews pipeline therapeutics for Huntington Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Huntington Disease therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Huntington Disease
- The report reviews pipeline therapeutics for Huntington Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Huntington Disease therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Huntington Disease
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Devise corrective measures for pipeline projects by understanding Huntington Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Devise corrective measures for pipeline projects by understanding Huntington Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Addex Therapeutics Ltd AFFiRiS AG Angita B.V. Astellas Pharma Inc. Azevan Pharmaceuticals, Inc. BioCrea GmbH BioMarin Pharmaceutical Inc. BrainStorm Cell Therapeutics Inc. Diffusion Pharmaceuticals Inc. EncephRx, Inc. Evotec AG Galenea Corp. Genervon Biopharmaceuticals, LLC Immungenetics AG Ionis Pharmaceuticals, Inc. Ipsen S.A. Kadmon Corporation, LLC KineMed, Inc. Living Cell Technologies Limited Medesis Pharma S.A. Mitochon Pharmaceuticals, Inc. Neuralstem, Inc. Neurimmune Holding AG NeuroNascent, Inc. New World Laboratories, Inc. nLife Therapeutics, S.L. NsGene A/S Omeros Corporation Oryzon Genomics S.A. Otsuka Holdings Co., Ltd. Pfizer Inc. PharmatrophiX, Inc. ProQR Therapeutics N.V. QR Pharma, Inc. Raptor Pharmaceutical Corp. reMYND NV Rhenovia Pharma Limited Sangamo BioSciences, Inc. SOM Innovation Biotech SL Spark Therapeutics, Inc. Teva Pharmaceutical Industries Ltd. TyrNovo Ltd. Ultragenyx Pharmaceutical Inc. UniQure N.V. Vaccinex, Inc. Vertex Pharmaceuticals Incorporated VistaGen Therapeutics , Inc. VivaCell Biotechnology Espana S.L. Voyager Therapeutics, Inc. Vybion, Inc. WAVE Life Sciences Ltd. Wellstat Therapeutics Corporation
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 08:17
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home